Arbaclofen Placarbil in GERD: A Randomized, Double-Blind, Placebo-Controlled Study

@article{Vakil2011ArbaclofenPI,
  title={Arbaclofen Placarbil in GERD: A Randomized, Double-Blind, Placebo-Controlled Study},
  author={Nimish Vakil and F. Jacob Huff and Amy Bian and Drew S. Jones and David Stamler},
  journal={The American Journal of Gastroenterology},
  year={2011},
  volume={106},
  pages={1427-1438}
}
OBJECTIVES:It has been shown that arbaclofen placarbil (AP) inhibits reflux in gastroesophageal reflux disease (GERD) following single oral dosing. This study evaluated the efficacy and safety of AP over 4 weeks in subjects with symptomatic GERD.METHODS:One hundred fifty-six subjects with heartburn and/or regurgitation ≥3 days/week and either no history of taking proton pump inhibitors (PPIs naive, n=58) or at least partial symptom response to PPI therapy (PPI responsive, n=98) were enrolled in… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Management of refractory typical GERD symptoms

  • Nature Reviews Gastroenterology &Hepatology
  • 2016

Medical treatments of GERD: the old and new.

  • Gastroenterology clinics of North America
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Systematic review of endoscopic treatments for gastrooesophageal refl ux disease

D Chen, C Barber, P McLoughlin
  • Br J Surg
  • 2009

R - baclofen prodrug XP 19986 is well tolerated and has dose proportional pharmacokinetics aft er multiple oral dosing

R Lal, FJ Huff, J Sukbuntherng
  • J Clin Pharmacol
  • 2008